Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 11,048 Shares

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 11,048 shares of Immunome stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $27.25, for a total value of $301,058.00. Following the sale, the director directly owned 92,211 shares of the company’s stock, valued at approximately $2,512,749.75. This trade represents a 10.70% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Tuesday, August 11th, Isaac Barchas sold 62,291 shares of Immunome stock. The stock was sold at an average price of $26.23, for a total value of $1,633,892.93.
• On Monday, August 10th, Isaac Barchas sold 10,125 shares of Immunome stock. The shares were sold at an average price of $26.07, for a total value of $263,958.75.
• On Friday, August 7th, Isaac Barchas sold 15,248 shares of Immunome stock. The shares were sold at an average price of $26.06, for a total value of $397,362.88.
• On Thursday, August 6th, Isaac Barchas sold 20,840 shares of Immunome stock. The stock was sold at an average price of $26.06, for a total value of $543,090.40.
• On Tuesday, July 7th, Isaac Barchas sold 16,906 shares of Immunome stock. The stock was sold at an average price of $24.20, for a total value of $409,125.20.
• On Monday, July 6th, Isaac Barchas sold 83,094 shares of Immunome stock. The shares were sold at an average price of $24.11, for a total transaction of $2,003,396.34.
• On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The shares were sold at an average price of $22.59, for a total transaction of $2,259,000.00.
• On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The stock was sold at an average price of $21.12, for a total transaction of $2,134,176.00.

Immunome Stock Performance

Shares of IMNM opened at $27.99 on Thursday. Immunome, Inc. has a fifty-two week low of $8.66 and a fifty-two week high of $28.04. The firm has a market cap of $3.17 billion, a price-to-earnings ratio of -11.06 and a beta of 2.08. The firm has a 50 day moving average price of $21.89 and a 200-day moving average price of $22.20.

Immunome (NASDAQ:IMNM) last released its earnings results on Tuesday, August 11th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.14). As a group, equities research analysts predict that Immunome, Inc. will post -2.06 earnings per share for the current year.

Hedge Funds Weigh In On Immunome

Several hedge funds and other institutional investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Immunome by 44.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 46,821 shares of the company’s stock worth $316,000 after purchasing an additional 14,398 shares during the period. Creative Planning purchased a new position in Immunome during the 2nd quarter valued at about $167,000. Rhumbline Advisers raised its position in Immunome by 22.0% during the 2nd quarter. Rhumbline Advisers now owns 108,414 shares of the company’s stock valued at $1,008,000 after purchasing an additional 19,526 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in Immunome by 3.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 280,816 shares of the company’s stock valued at $2,612,000 after purchasing an additional 9,686 shares during the last quarter. Finally, Balyasny Asset Management L.P. bought a new position in Immunome during the 2nd quarter valued at approximately $1,021,000. 44.58% of the stock is owned by institutional investors.

Key Headlines Impacting Immunome

Here are the key news stories impacting Immunome this week:

• Positive Sentiment: Truist raised its price target to $38 from $37 and maintained a “Buy” rating, implying substantial additional upside from recent levels. The upgraded outlook likely provided the strongest near-term support for Immunome (IMNM). Benzinga analyst price target update
• Positive Sentiment: Immunome reported its second-quarter 2026 results and provided a business update. Investors are likely focused on progress in the company’s clinical-stage antibody programs and its development pipeline, which remain key drivers of the stock’s valuation. Immunome second-quarter 2026 results and business update
• Neutral Sentiment: Director Isaac Barchas sold a combined 98,712 shares from August 10 through August 12 for approximately $2.6 million. The sales reduced his direct ownership to 92,211 shares, but each transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, which may make the activity less indicative of a change in his outlook. The transactions were disclosed in SEC filings. Immunome director insider sales SEC filing
• Negative Sentiment: Immunome reported a quarterly loss of $0.65 per share, missing the consensus estimate of a $0.51 loss. The larger-than-expected loss underscores the company’s ongoing cash-burn and execution risks typical of a clinical-stage biotechnology company. Immunome quarterly earnings release

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on IMNM shares. HC Wainwright reaffirmed a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. Wall Street Zen cut Immunome from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Barclays began coverage on Immunome in a research note on Thursday, May 28th. They issued an “overweight” rating and a $36.00 price target on the stock. Truist Financial increased their price objective on Immunome from $37.00 to $38.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Leerink Partners dropped their price objective on Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research note on Friday, May 15th. Twelve analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Immunome currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.64.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.